Skip to main content

Table 3 Vaccine prices required to achieve cost-effectiveness a

From: Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis

Risk group Cost per DALY (excluding asthma) Cost per DALY (including asthma) Palivizumab price to achieve cost-Effectiveness (including asthma) % decrease in Palivizumab Price
50 mg
Vial b
100 mg
Vial c
CHD $266,020 $218,968 $278 $512 46.5%
CLD $472,139 $287,057 $270 $497 48.1%
<29 $585,537 $226,900 $329 $605 36.8%
29–32 $685,961 $347,593 $237 $436 54.5%
33–36 $2,092,809 $1,149,584 $87 $160 83.3%
No risk $7,503,953 $3,023,294 $31 $57 94.0%
  1. a based on threshold of $105,986 per averted DALY and 2945 annual hospitalizations in children under two
  2. b current price (excluding VAT) of $520 per vial
  3. c current price (excluding VAT) of $959 per vial